Exchange Bulletin
Zymeworks Inc. (ZYME) To Trade On Toronto Stock Exchange
May 1, 2017
| Issuer: | Zymeworks Inc. (the "Company") |
| Security: | Common shares ("Common Shares") |
| Symbol: | ZYME |
| Issue price per security: | US$13.00 |
| Number of securities issued and outstanding: | 24,940,252 |
| Number of securities reserved for issuance: | 5,585,268 |
| Listing category: | Industrial, Non-exempt |
| CUSIP: | 98985W 10 2 |
| Trading currency: | CDN $ |
| Transaction: | Initial public offering of Common Shares (the "Offering") |
| Listing date: | May 2, 2017 (as at 5:01 p.m.) in anticipation of closing of the Offering |
| Anticipated closing date: | May 3, 2017 (prior to the opening) |
| Posted for trading date: | May 3, 2017 (at the opening) subject to confirmation of closing of the Offering |
| End of trading on an "if, as and when issued" basis: | The Common Shares commenced trading on TSX on an "if, as and when issued" basis on Friday, April 28, 2017. Subject to the closing of the Offering occurring as scheduled prior to the opening of business on Wednesday, May 3, 2017, trading on an "if, as and when issued" basis will conclude at the close of business on Tuesday, May 2, 2017, unless the closing of the Offering has been delayed. |
| Other market(s): | New York Stock Exchange |
| Temporary market maker: | Altacorp Capital Inc. |
| Security ownership registration: | Certificated Issue |
| Investor relations: | David Matousek (604) 449-5564 Email: david.matousek@zymeworks.com |
| Incorporation: | Business Corporations Act (British Columbia) |
| Fiscal year end: | December 31 |
| Nature of business: | The Company is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. |
| Transfer agent and registrar: | Computershare Investor Services Inc. at its principal offices in Toronto and Vancouver. |
| Dividends: | The Company does not expect to pay any dividends on its Common Shares in the foreseeable future. |
| Sponsorship: | Not applicable |
| Disclosure document: | Supplemented PREP Prospectus dated April 27, 2017 which is available at www.SEDAR.com. Capitalized terms not otherwise defined herein are as defined in the disclosure document. |
| Initial public offering: | The Offering will be comprised of 4,500,000 Common Shares at an Offering price of US$13.00 per Common Share, for gross proceeds of US$58.5 million. In addition, the Company has granted to the underwriters an over-allotment option pursuant to which the underwriters may purchase up to 675,000 additional Common Shares at the Offering price. |
| TSX contact: | Julie K. Shin, Director, Listed Issuer Services, Toronto Stock Exchange |
